Fractional FLow Reserve And IVUS for Clinical OUtcomes in Patients With InteRmediate Stenosis

NCT02673424 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1700

Last updated 2025-02-10

No results posted yet for this study

Summary

To compare the safety and efficacy of FFR (fractional flow reserve)-guided percutaneous coronary intervention (PCI) strategy with IVUS (intravascular ultrasound \[IVUS\])-guided PCI in patients with intermediate coronary stenosis.

Conditions

  • Stable Angina

Interventions

PROCEDURE

FFR-guided stenting

The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the FFR-guided strategy arm \* Criteria for revascularization: The FFR ≤ 0.80 will be targeted for PCI

PROCEDURE

IVUS-guided stenting

The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm \* Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or (MLA ≤ 4mm2 AND Plaque burden \>70%)

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER
  • Samsung Medical Center, Sungkyunkwan University School of Medicine

    collaborator UNKNOWN
  • Ulsan University Hospital

    collaborator OTHER
  • Keimyung University Dongsan Medical Center

    collaborator OTHER
  • Inje University

    collaborator OTHER
  • KangWon National University Hospital

    collaborator OTHER
  • Ajou University School of Medicine

    collaborator OTHER
  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Bon-Kwon Koo, MD, PhD · Seoul National University Hospital

  • Seung-Jea Tahk, MD, PhD · Ajou University School of Medicine

  • JianAn Wang, MD, PhD · Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2025-02-28
Completion
2025-12-31

Countries

  • China
  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02673424 on ClinicalTrials.gov